Skip to content

Study · Animal study (in vivo) · rat · 2026

7 results

Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.

Mills AR, de Souza A, Pham T, Mugisho OO

Experimental physiology19 Jun 2026Cited by 1 (Europe PMC)

PMID42321010 (opens in a new tab)PMCIDPMC13394035 (opens in a new tab)DOI10.1113/ep093714 (opens in a new tab)PepBankPUB-42321010
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Type 2 diabetes mellitus (T2DM) is associated with chronic systemic and cardiac inflammation, contributing to the development of diabetic cardiomyopathy. The mitochondrial-derived peptide mitochondrial open reading frame of the 12S rRNA type-C (MOTS-c) has emerged as a promising regulator of metabolic and inflammatory pathways. In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model. MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)-10 and IL-1β. Immunohistochemical analysis revealed reduced levels of NLRP3, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), and cleaved caspase-1 in left ventricular tissue following MOTS-c administration. Correlation analyses linked IL-18 and IL-1β with elevated markers, including low-density lipoprotein and uric acid, suggesting interplay between overall health and inflammasome activity. These results indicate that MOTS-c modulates both systemic and cardiac inflammation in T2DM, providing a novel therapeutic approach for reducing cardiovascular risk in diabetic patients.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with high-fat diet and streptozotocin-induced type 2 diabetes, MOTS‑c treatment reduced fasting blood glucose.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c lowered fasting blood glucose.

    Peptide
    MOTS-c
    Outcome
    DecreaseFasting blood glucose
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)-10 and IL-1β.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with high-fat diet and streptozotocin-induced type 2 diabetes, MOTS‑c treatment reduced circulating C-reactive protein.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c lowered the blood level of C-reactive protein, a marker of inflammation.

    Peptide
    MOTS-c
    Outcome
    DecreaseCirculating C-reactive protein
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)-10 and IL-1β.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with high-fat diet and streptozotocin-induced type 2 diabetes, MOTS‑c treatment selectively modulated plasma interleukin-10; the direction is not stated.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c changed plasma interleukin-10, an inflammation signal. The abstract does not give the direction.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedPlasma interleukin-10
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)-10 and IL-1β.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with high-fat diet and streptozotocin-induced type 2 diabetes, MOTS‑c treatment selectively modulated plasma interleukin-1β; the direction is not stated.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c changed plasma interleukin-1β, an inflammation signal. The abstract does not give the direction.

    Peptide
    MOTS-c
    Outcome
    Direction not reportedPlasma interleukin-1β
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)-10 and IL-1β.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats with type 2 diabetes, MOTS‑c administration reduced NLRP3 in left ventricular tissue.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c lowered NLRP3, an inflammation protein, in heart tissue.

    Peptide
    MOTS-c
    Outcome
    DecreaseNLRP3 in left ventricular tissue
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Immunohistochemical analysis revealed reduced levels of NLRP3, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), and cleaved caspase-1 in left ventricular tissue following MOTS-c administration.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats with type 2 diabetes, MOTS‑c administration reduced ASC in left ventricular tissue.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c lowered ASC, an inflammation protein, in heart tissue.

    Peptide
    MOTS-c
    Outcome
    DecreaseASC in left ventricular tissue
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Immunohistochemical analysis revealed reduced levels of NLRP3, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), and cleaved caspase-1 in left ventricular tissue following MOTS-c administration.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats with type 2 diabetes, MOTS‑c administration reduced cleaved caspase-1 in left ventricular tissue.

    In plain wordsIn rats with type 2 diabetes, MOTS‑c lowered cleaved caspase-1, an inflammation protein, in heart tissue.

    Peptide
    MOTS-c
    Outcome
    DecreaseCleaved caspase-1 in left ventricular tissue
    Study

    ratn: not reported in source

    High-fat diet and streptozotocin-induced type 2 diabetes
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Immunohistochemical analysis revealed reduced levels of NLRP3, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), and cleaved caspase-1 in left ventricular tissue following MOTS-c administration.
    1 context sentence
    Summary · context
    In this study, we investigated the effects of MOTS-c treatment on leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in a high-fat diet and streptozotocin-induced T2DM rat model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.